Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy
This study suggests no significant differences in long-term cancer outcomes between EOD and QW schedules for five-fraction prostate SABR. This trial is registered on ClinicalTrials.gov as NCT01423474.
Authors
- Harvey Quon (ORCID: https://orcid.org/0000-0001-9934-0926)
- Boyd McCurdy
- Meghan Kulasingham-Poon
- Melanie Davidson (ORCID: https://orcid.org/0000-0002-0587-6840)
- Ananth K. Ravi (ORCID: https://orcid.org/0000-0003-4583-5741)
- Andrew Loblaw (ORCID: https://orcid.org/0000-0002-4883-1781)
- Aldrich Ong (ORCID: https://orcid.org/0000-0002-9879-9222)
- Yasir Alayed (ORCID: https://orcid.org/0000-0002-4315-0485)
- Wee Loon Ong (ORCID: https://orcid.org/0000-0001-6657-7193)
- Alexandre Mamedov (ORCID: https://orcid.org/0000-0002-7395-3617)
- Dilip Panjwani
- Hans T. Chung (ORCID: https://orcid.org/0000-0002-9701-5406)
- Danny Vesprini (ORCID: https://orcid.org/0000-0001-9714-2782)
- William Chu (ORCID: https://orcid.org/0000-0002-9307-0184)
- Liying Zhang (ORCID: https://orcid.org/0000-0001-8520-267X)
- Renée Korol
- Geordi Pang (ORCID: https://orcid.org/0009-0000-8405-3000)
- Patrick Cheung
- Andrea Deabreu
- Amit Chowdhury
Institutions
- BC Cancer Agency (CA)
- Sunnybrook Health Science Centre (CA)
- Health Sciences Centre (CA)
- CancerCare Manitoba (CA)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1016/j.euo.2025.03.011
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Prostate Cancer Canada